Terri S Armstrong1, Yuan Ying1, Jimin Wu1, Alvina A Acquaye1, Elizabeth Vera-Bolanos1, Mark R Gilbert1, Paul D Brown1, Janette Vardy1, Caroline Chung1. 1. University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.); National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney Concord Repatriation General Hospital, Concord, New South Wales, Australia (J.V.); Department of Radiation Oncology, University of Toronto/University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
Abstract
BACKGROUND: Corticosteroids can have many side effects that impact the patient's quality of life and functional status. The Dexamethasone Symptom Questionnaire-Chronic (DSQ-C) was developed to report corticosteroid side effects. This study's objective was to evaluate the utility of the DSQ-C and report associated signs and symptoms in brain tumor patients. METHODS: Data collection included demographic and disease characteristics and the DSQ-C. Descriptive statistics were used to report associations among variables. Linear regression models were applied to assess the effects of the cumulative daily dose (mg/d × total d) on DSQ-C scores. Psychometrics included factor analysis to assess construct validity and Cronbach's alpha for internal consistency. RESULTS: Ninety-six adult patients with primary (77%) or metastatic (23%) brain tumors participated, with 74% on corticosteroids. Participants were primarily white (83%) males (65%) between 20 and 75 years of age (median, 53). Median corticosteroid dose duration was 4 mg/day for 1 month (range, 0-26 mo). The DSQ-C scores ranged from 17 to 54 (mean of 27), with 35% reporting increased appetite and trouble sleeping. Factor analysis indicated 6 underlying constructs explaining 53% of variance. DSQ-C internal consistency (reliability) was 0.77. The DSQ-C discriminated between patients who were on steroids and those who were not (P < .01), and cumulative dose predicted DSQ-C scores (P < .001). CONCLUSIONS: This study demonstrated the potential use of the DSQ-C as a screening tool for side effects associated with corticosteroid use in brain tumor patients. Future analyses should include longitudinal evaluation of severity and biologic underpinnings of variability of timing and severity of symptoms.
BACKGROUND: Corticosteroids can have many side effects that impact the patient's quality of life and functional status. The Dexamethasone Symptom Questionnaire-Chronic (DSQ-C) was developed to report corticosteroid side effects. This study's objective was to evaluate the utility of the DSQ-C and report associated signs and symptoms in brain tumorpatients. METHODS: Data collection included demographic and disease characteristics and the DSQ-C. Descriptive statistics were used to report associations among variables. Linear regression models were applied to assess the effects of the cumulative daily dose (mg/d × total d) on DSQ-C scores. Psychometrics included factor analysis to assess construct validity and Cronbach's alpha for internal consistency. RESULTS: Ninety-six adult patients with primary (77%) or metastatic (23%) brain tumors participated, with 74% on corticosteroids. Participants were primarily white (83%) males (65%) between 20 and 75 years of age (median, 53). Median corticosteroid dose duration was 4 mg/day for 1 month (range, 0-26 mo). The DSQ-C scores ranged from 17 to 54 (mean of 27), with 35% reporting increased appetite and trouble sleeping. Factor analysis indicated 6 underlying constructs explaining 53% of variance. DSQ-C internal consistency (reliability) was 0.77. The DSQ-C discriminated between patients who were on steroids and those who were not (P < .01), and cumulative dose predicted DSQ-C scores (P < .001). CONCLUSIONS: This study demonstrated the potential use of the DSQ-C as a screening tool for side effects associated with corticosteroid use in brain tumorpatients. Future analyses should include longitudinal evaluation of severity and biologic underpinnings of variability of timing and severity of symptoms.
Authors: J Vardy; G Pond; A Dodd; D Warr; B Seruga; M Clemons; L Bordeleau; P Goodwin; I F Tannock Journal: Breast Cancer Res Treat Date: 2012-09-06 Impact factor: 4.872
Authors: Alina Sturdza; Barbara-Ann Millar; Neelufer Bana; Normand Laperriere; Gregory Pond; Rebecca K S Wong; Andrea Bezjak Journal: Support Care Cancer Date: 2008-02-07 Impact factor: 3.603
Authors: Nils D Arvold; Terri S Armstrong; Katherine E Warren; Susan M Chang; Lisa M DeAngelis; Jaishri Blakeley; Marc C Chamberlain; Erin Dunbar; Herbert H Loong; David R Macdonald; David A Reardon; Michael A Vogelbaum; Ying Yuan; Michael Weller; Martin van den Bent; Patrick Y Wen Journal: Neuro Oncol Date: 2018-06-18 Impact factor: 12.300
Authors: James L Rogers; Julianie De La Cruz Minyety; Elizabeth Vera; Alvina A Acquaye; Samuel S Payén; Jeffrey S Weinberg; Terri S Armstrong; Shiao-Pei S Weathers Journal: Neurooncol Pract Date: 2022-02-17
Authors: Terri S Armstrong; Marcia Y Shade; Ghislain Breton; Mark R Gilbert; Anita Mahajan; Michael E Scheurer; Elizabeth Vera; Ann M Berger Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300
Authors: Megan S Jeon; Haryana M Dhillon; Eng-Siew Koh; Anna K Nowak; Elizabeth Hovey; Joseph Descallar; Lisa Miller; Nathaniel S Marshall; Meera R Agar Journal: Neurooncol Pract Date: 2020-09-12
Authors: Kuan-Wen Wang; Marlie Valencia; Laura Banfield; Ruth Chau; Adam Fleming; Sheila K Singh; Sarah Burrow; Russell J de Souza; Lehana Thabane; M Constantine Samaan Journal: Syst Rev Date: 2016-06-14
Authors: Linda Dirven; Ralf Luerding; Dagmar Beier; Elisabeth Bumes; Christiane Reinert; Clemens Seidel; Matteo Mario Bonsanto; Michael Bremer; Stefan Rieken; Stephanie E Combs; Ulrich Herrlinger; Corinna Seliger; Holger Kuntze; Regine Mayer-Steinacker; Annette Dieing; Claudius Bartels; Oliver Schnell; Astrid Weyerbrock; Sabine Seidel; Oliver Grauer; Minou Nadji-Ohl; Frank Paulsen; Michael Weller; Wolfgang Wick; Peter Hau Journal: J Neurooncol Date: 2020-05-04 Impact factor: 4.130
Authors: Megan S Jeon; Haryana M Dhillon; Joseph Descallar; Lawrence Lam; Samuel Allingham; Eng-Siew Koh; David C Currow; Meera R Agar Journal: Neurooncol Pract Date: 2019-02-19